AstraZeneca strikes $272M deal for Ardelyx kidney drug

Deal-hungry AstraZeneca ($AZN) nabbed a potential treatment for chronic kidney disease in a $272 million deal with Ardelyx. Under the new partnership, Adelyx gets $35 million up front, plus up to $237.5 million in milestones, provided the RX5791 drug makes it to market. Report